BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Herbst DA, Reddy KR. Risk factors for hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2012;1:180-182. [PMID: 31186882 DOI: 10.1002/cld.111] [Cited by in Crossref: 37] [Cited by in F6Publishing: 19] [Article Influence: 4.1] [Reference Citation Analysis]
2 Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia–Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57-73. [DOI: 10.1038/s41575-018-0055-0] [Cited by in Crossref: 123] [Cited by in F6Publishing: 110] [Article Influence: 30.8] [Reference Citation Analysis]
3 Lapiński TW, Pogorzelska J, Flisiak R. HBV mutations and their clinical significance. Adv Med Sci 2012;57:18-22. [PMID: 22430043 DOI: 10.2478/v10039-012-0006-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
4 Schwartz ME, Shrager B. Surgical resection for hepatocellular carcinoma in the noncirrhotic: the Western experience. Recent Results Cancer Res 2013;190:85-100. [PMID: 22941015 DOI: 10.1007/978-3-642-16037-0_6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Shin HS, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Baatarkhuu O, Ahn SH. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1528-34. [PMID: 22497450 DOI: 10.1111/j.1440-1746.2012.07145.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
6 Bianca C, Sidhartha E, Tiribelli C, El-Khobar KE, Sukowati CHC. Role of hepatitis B virus in development of hepatocellular carcinoma: Focus on covalently closed circular DNA . World J Hepatol 2022; 14(5): 866-884 [DOI: 10.4254/wjh.v14.i5.866] [Reference Citation Analysis]
7 Chuang H, Huang LS, Kapoor M, Liao Y, Yang C, Chang C, Wu C, Hwu JR, Huang T, Hsu M. Design and synthesis of pyridine-pyrazole-sulfonate derivatives as potential anti-HBV agents. Med Chem Commun 2016;7:832-6. [DOI: 10.1039/c6md00008h] [Cited by in Crossref: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Ooi KL, Loh SI, Sattar MA, Muhammad TST, Sulaiman SF. Cytotoxic, caspase-3 induction and in vivo hepatoprotective effects of phyllanthin, a major constituent of Phyllanthus niruri. Journal of Functional Foods 2015;14:236-43. [DOI: 10.1016/j.jff.2015.01.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
9 Wang Y, Yu W, Shen C, Wang W, Zhang L, Liu F, Sun H, Zhao Y, Che H, Zhao C. Predictive Value of Serum IFN-γ inducible Protein-10 and IFN-γ/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients. Sci Rep 2017;7:40404. [PMID: 28067328 DOI: 10.1038/srep40404] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
10 Wu Q, Liu Q. Do hepatitis B virus and hepatitis C virus co-infections increase hepatocellular carcinoma occurrence through synergistically modulating lipogenic gene expression?: HBV HCV co-infection and HCC. Hepatology Research 2012;42:733-40. [DOI: 10.1111/j.1872-034x.2012.00994.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George J, Dore GJ. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol 2011;26:1757-64. [PMID: 21615789 DOI: 10.1111/j.1440-1746.2011.06785.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
12 Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol 2012; 4(3): 74-80 [PMID: 22489259 DOI: 10.4254/wjh.v4.i3.74] [Cited by in Crossref: 202] [Cited by in F6Publishing: 201] [Article Influence: 20.2] [Reference Citation Analysis]
13 Alavian SM, Showraki A. Hepatitis B and its Relationship With Oxidative Stress. Hepat Mon 2016;16:e37973. [PMID: 27822264 DOI: 10.5812/hepatmon.37973] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
14 Yu Q, Qian W, Wang J, Wu Y, Zhang J, Chen W. An indel polymorphism in the 3' untranslated region of JAK1 confers risk for hepatocellular carcinoma possibly by regulating JAK1 transcriptional activity in a Chinese population. Oncol Lett 2018;15:8088-94. [PMID: 29731916 DOI: 10.3892/ol.2018.8347] [Reference Citation Analysis]
15 Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther 2018;47:1181-200. [PMID: 29479728 DOI: 10.1111/apt.14577] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
16 Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther 2011;11:524-34. [PMID: 21258214 DOI: 10.4161/cbt.11.5.14677] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 6.2] [Reference Citation Analysis]
17 Li T, Meng QH, Zou ZQ, Fan YC, Long B, Guo YM, Hou W, Zhao J, Li J, Yu HW. Correlation between promoter methylation of glutathione-S-tranferase P1 and oxidative stress in acute-on-chronic hepatitis B liver failure. J Viral Hepat. 2011;18:e226-e231. [PMID: 21692937 DOI: 10.1111/j.1365-2893.2011.01438.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
18 Tao R, Hu S, Wang S, Zhou X, Zhang Q, Wang C, Zhao X, Zhou W, Zhang S, Li C, Zhao H, He Y, Zhu S, Xu J, Jiang Y, Li L, Gao Y. Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. Carcinogenesis 2015;36:1136-43. [PMID: 26163879 DOI: 10.1093/carcin/bgv099] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 10.1] [Reference Citation Analysis]
19 Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 2015; 21(15): 4644-4651 [PMID: 25914474 DOI: 10.3748/wjg.v21.i15.4644] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
20 Nie H, Evans AA, London WT, Block TM, Ren XD. Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach. J Clin Microbiol 2011;49:2440-8. [PMID: 21562108 DOI: 10.1128/JCM.02472-10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Dong D, Gao X, Zhu Z, Yu Q, Bian S, Gao Y. A 40-bp insertion/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population. Gene. 2012;497:66-70. [PMID: 22285926 DOI: 10.1016/j.gene.2012.01.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
22 Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World J Gastroenterol 2021; 27(17): 2025-2038 [PMID: 34007137 DOI: 10.3748/wjg.v27.i17.2025] [Reference Citation Analysis]
23 Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One. 2012;7:e34779. [PMID: 22506050 DOI: 10.1371/journal.pone.0034779] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
24 Cao W, Yu P, Yang K, Cao D. Aflatoxin B1: metabolism, toxicology, and its involvement in oxidative stress and cancer development. Toxicol Mech Methods 2021;:1-42. [PMID: 34930097 DOI: 10.1080/15376516.2021.2021339] [Reference Citation Analysis]
25 Shoaei SD, Sali S, Karamipour M, Riahi E. Non-invasive histologic markers of liver disease in patients with chronic hepatitis B. Hepat Mon 2014;14:e14228. [PMID: 24693307 DOI: 10.5812/hepatmon.14228] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
26 Qiao H, Li H, Wen X, Tan X, Yang C, Liu N, Abranches J. Multi-Omics Integration Reveals the Crucial Role of Fusobacterium in the Inflammatory Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Microbiol Spectr. [DOI: 10.1128/spectrum.01068-22] [Reference Citation Analysis]
27 Wang HW, Peng CY, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen CH, Hsu WF, Huang GT. New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis. Sci Rep 2017;7:3259. [PMID: 28607450 DOI: 10.1038/s41598-017-03589-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
28 Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012;55:476-82. [PMID: 21953588 DOI: 10.1002/hep.24710] [Cited by in Crossref: 174] [Cited by in F6Publishing: 168] [Article Influence: 17.4] [Reference Citation Analysis]
29 Gao X, Huang M, Liu L, He Y, Yu Q, Zhao H, Zhou C, Zhang J, Zhu Z, Wan J, Jiang X, Gao Y. Insertion/deletion polymorphisms in the promoter region of BRM contribute to risk of hepatocellular carcinoma in Chinese populations. PLoS One 2013;8:e55169. [PMID: 23359823 DOI: 10.1371/journal.pone.0055169] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
30 Chamberlain J, Sarfati D, Cunningham R, Koea J, Gurney J, Blakely T. Incidence and management of hepatocellular carcinoma among Māori and non-Māori New Zealanders. Aust N Z J Public Health 2013;37:520-6. [PMID: 24892150 DOI: 10.1111/1753-6405.12108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
31 Walker PF. Pre‐travel Consultation and Hepatitis B: A Double Opportunity for Preventing Infection in At‐Risk Patients and Life‐Threatening Complications in HBV Carriers. J Travel Med 2013;20:143-5. [DOI: 10.1111/jtm.12027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Sarmady M, Dampier W, Tozeren A. Sequence- and interactome-based prediction of viral protein hotspots targeting host proteins: a case study for HIV Nef. PLoS One 2011;6:e20735. [PMID: 21738584 DOI: 10.1371/journal.pone.0020735] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
33 Lin G, Xiao H, Zeng Z, Xu Z, He J, Sun T, Liu J, Guo G, Ji W, Hu Y. Constraints for symptomatic radiation pneumonitis of helical tomotherapy hypofractionated simultaneous multitarget radiotherapy for pulmonary metastasis from hepatocellular carcinoma. Radiother Oncol. 2017;123:246-250. [PMID: 28314468 DOI: 10.1016/j.radonc.2017.02.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
34 Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163-186. [PMID: 28042609 DOI: 10.20517/2394-5079.2016.05] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 10.7] [Reference Citation Analysis]
35 El-Fattah MA, Aboelmagd M, Elhamouly M. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. United European Gastroenterol J 2017;5:227-35. [PMID: 28344790 DOI: 10.1177/2050640616659024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
36 Zhang Z, Xu L, Wang Z. Screening serum biomarkers for early primary hepatocellular carcinoma using a phage display technique. J Clin Lab Anal 2011;25:402-8. [PMID: 22086793 DOI: 10.1002/jcla.20491] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
37 Li Z, Zhang K, Lin S, Mi D, Cao N, Wen Z, Li Z. Radiofrequency ablation combined with percutaneous ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis. International Journal of Hyperthermia 2017;33:237-46. [DOI: 10.1080/02656736.2016.1237681] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
38 Mohamed BF, Serag WM, Abdelal RM, Elsergany HF. S100A14 protein as diagnostic and prognostic marker in hepatocellular carcinoma. Egypt Liver Journal 2019;9. [DOI: 10.1186/s43066-019-0015-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
39 Xiang ZW, Sun L, Li GH, Maharjan R, Huang JH, Li CX. Progress in the treatment of pulmonary metastases after liver transplantation for hepatocellular carcinoma. World J Hepatol 2015; 7(20): 2309-2314 [PMID: 26380655 DOI: 10.4254/wjh.v7.i20.2309] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
40 Park CH, Jeong SH, Yim HW, Kim JD, Bae SH, Choi JY, Yoon SK. Family history influences the early onset of hepatocellular carcinoma. World J Gastroenterol 2012; 18(21): 2661-2667 [PMID: 22690075 DOI: 10.3748/wjg.v18.i21.2661] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
41 Nie H, Evans AA, London WT, Block TM, Ren XD. Quantification of complex precore mutations of hepatitis B virus by SimpleProbe real time PCR and dual melting analysis. J Clin Virol 2011;51:234-40. [PMID: 21665530 DOI: 10.1016/j.jcv.2011.05.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]